Next Article in Journal
Extracellular-Ca2+-Induced Decrease in Small Molecule Electrotransfer Efficiency: Comparison between Microsecond and Nanosecond Electric Pulses
Next Article in Special Issue
π-Donor/π-Acceptor Interactions for the Encapsulation of Neurotransmitters on Functionalized Polysilicon-Based Microparticles
Previous Article in Journal
Biphasic Dissolution as an Exploratory Method during Early Drug Product Development
Previous Article in Special Issue
Crosslinked Hyaluronan Electrospun Nanofibers for Ferulic Acid Ocular Delivery
Open AccessArticle

Encapsulating TGF-β1 Inhibitory Peptides P17 and P144 as a Promising Strategy to Facilitate Their Dissolution and to Improve Their Functionalization

1
Nanomedicine Department, Institute of Nanoscience and Nanotechnology, Kafrelsheikh University, Kafrelsheikh 33516, Egypt
2
Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona (UB) and CIBEREHD, Gran Via de l’Hospitalet, 199, Hospitalet de Llobregat, 08908 Barcelona, Spain
3
CNR NANOTEC-Istituto di Nanotecnologia, Via Monteroni, 73100 Lecce, Italy
*
Authors to whom correspondence should be addressed.
Pharmaceutics 2020, 12(5), 421; https://doi.org/10.3390/pharmaceutics12050421
Received: 24 March 2020 / Revised: 28 April 2020 / Accepted: 29 April 2020 / Published: 2 May 2020
(This article belongs to the Special Issue Nano-Micro Encapsulation of Drugs)
Transforming growth factor-beta (TGFβ1) is considered as a master regulator for many intracellular signaling pathways, including proliferation, differentiation and death, both in health and disease. It further represents an oncogenic factor in advanced tumors allowing cancer cells to be more invasive and prone to move into the metastatic process. This finding has received great attention for discovering new therapeutic molecules against the TGFβ1 pathway. Among many TGFβ1 inhibitors, peptides (P17 and P144) were designed to block the TGFβ1 pathway. However, their therapeutic applications have limited use, due to lack of selection for their targets and their possible recognition by the immune system and further due to their potential cytotoxicity on healthy cells. Besides that, P144 is a highly hydrophobic molecule with less dissolution even in organic solution. Here, we aimed to overcome the dissolution of P144, as well as design nano-delivery strategies to protect normal cells, to increase cellular penetration and to raise the targeted therapy of both P17 and P144. Peptides were encapsulated in moieties of polymer hybrid protein. Their assembly was investigated by TEM, microplate spectrum analysis and fluorescence microscopy. SMAD phosphorylation was analyzed by Western blot as a hallmark of their biological efficiency. The results showed that the encapsulation of P17 and P144 might improve their potential therapeutic applications. View Full-Text
Keywords: transforming growth factors; proliferation; polymer hybrid protein transforming growth factors; proliferation; polymer hybrid protein
Show Figures

Figure 1

MDPI and ACS Style

Hanafy, N.A.N.; Fabregat, I.; Leporatti, S.; El Kemary, M. Encapsulating TGF-β1 Inhibitory Peptides P17 and P144 as a Promising Strategy to Facilitate Their Dissolution and to Improve Their Functionalization. Pharmaceutics 2020, 12, 421.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop